Wearable Injectors Market

Wearable Injectors Market by Product Type (On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology (Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) & Region - Global Forecast to 2026

Report Code: MD 6659 Jul, 2021, by marketsandmarkets.com

The global wearable injectors market in terms of revenue was estimated to be worth $7.2 billion in 2021 and is poised to reach $11.5 billion by 2026, growing at a CAGR of 9.9% from 2021 to 2026. The growth of this market is primarily driven by the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favourable reimbursement scenario in major markets, and technological advancements in injector devices. However, high costs, and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injectors to a certain extent.

Wearable Injectors Market

To know about the assumptions considered for the study, Request for Free Sample Report

Wearable injectors Market Dynamics

Drivers: Growing prevalence of chronic diseases

The growing prevalence of chronic diseases has led to a greater focus on wearable injector devices to effectively handle the growing patient pool and increase patient compliance to therapies. The treatment of chronic diseases such as diabetes and cardiovascular disorders includes a daily or weekly intake of injectables, which highlights the need for, and adoption of convenient and efficient injection technologies.

According to the International Diabetes Federation, in 2019, around 463 million people were suffering from diabetes worldwide; this is expected to increase to 700 million by 2045. The rising disease prevalence has prompted market players offering wearable injectors to focus on product launches, resulting in the introduction of products such as Amgen’s Repatha Pushtronex system (using West Pharmaceutical’s SmartDose Technology platform) and the Neulasta (pegfilgrastim) OnPro kit for the treatment of neutropenia in cancer. As disease prevalence increases in the coming years, so too will the demand for effective and advanced treatment modalities such as wearable injectors.

Restraints: High cost of wearable injectors

Wearable injectors are used as an alternative to requiring the patient to be admitted to a medical facility for clinical support. To achieve wide adoption, technology platforms need to minimize incremental cost increases to pharmaceutical companies, healthcare payers, and patients. Due to the higher cost of wearable injectors, compared to oral medication or that delivered by an autoinjector, their adoption is lower among end users.

Opportunities: Increasing demand for biologics and mAbs

According to PhRMA (Pharmaceutical Research and Manufacturers of America), as many as 907 biologics were in development in 2013; the number of biologic drugs in development is continuing to increase exponentially, with more than 2,700 remedies in development as of mid-2017, triple the 907 in development in 2013. mAb-based biotherapies account for 50% of the top 100 drugs and are projected to maintain a dominant position in the pharmaceutical market. Their efficacy in self-administration and convenience is likely to make wearable injectors prominent options for the delivery of such drugs.

Challenges: Unfavourable reimbursement structure in developing countries

A number of developing countries do not offer reimbursement for wearable injectors. For instance, in India, wearable insulin pumps are not reimbursed, and no specific guidelines regarding their use are given on prescription. In China, patients with Type 1 diabetes have to bear the entire cost of insulin pumps and supplies out-of-pocket. The lack of reimbursement directly affects access to and the adoption of wearable injectors and is thus expected to negatively impact the growth of the market in the coming years.

The on-body injectors holds the largest share in wearable injectors market by type, in the forecast period

The on-body accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time.

The spring-based technology segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the required drug subcutaneously.

The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to The high burden of diabetes across the globe, coupled with the growing availability of wearable injectors for the treatment of these diseases, is driving the growth of this market segment The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the rising preference for the self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery approaches, which lower the hospitalization rate and require minimal expertise, is expected to boost the growth of the home healthcare settings segment.

The off-body injectors segment is expected to grow at the highest CAGR during the forecast period

On the basis of type, the wearable injectors market is segmented into on-body and off-body injectors. The off-body injectors segment is projected to witness a higher growth rate during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.

On the basis of technology, expanding battery segment is accounted for the highest growth of the wearable injectors market

Based on technology, the global market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. The expanding battery segment accounted for the highest growth in the forecast period. This can be attributed to the increasing customer demand for these devices as they are more convenient to use.

On the basis of therapy, diabetes segment accounted for the largest share of the wearable injectors market

Based on therapy, the global market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (such as Parkinson’s disease, thalassemia, and primary immunodeficiency disorders). The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the growing availability of wearable injectors for the treatment of these diseases high burden of diabetes across the globe.

In 2020, the hospitals and clinics segment accounted for the largest share of the market

Based on end user, the wearable injectors market is segmented into hospitals and clinics and home healthcare settings. The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the increasing need to curb healthcare costs and rising preference for the self-administration of medication.

North America accounted for the largest share for players operating in the wearable injectors market

North America accounted for the largest share of the global market. The large share of the region is due to the shift of healthcare delivery toward homecare due to COVID-19, rising prevalence of chronic diseases, increasing concerns over the hazards related to the administration of conventional and novel drug molecules, favourable reimbursement scenario, and the presence of major market players in the region.

Wearable Injectors Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the Wearable injectors market: Ypsomed (Switzerland), Amgen (US), Subcuject (Denmark), Enable Injections (US), Medtronic plc (Ireland), Insulet Corporation (US), United Therapeutics Corp. (US), CeQur SA (Switzerland), Sensile Medical (Switzerland), ATS Automation (Canada), West Pharmaceutical Services, Inc. (US), Tandem Diabetes Care (US), Valeritas (US), Sonceboz (Switzerland), Noble (US), Elcam Drug Delivery Devices (Israel), Bespak Europe Ltd. (UK), Stevanato Group (Italy), Sorrel Medical (Israel), Weibel CDS AG (Switzerland), and Neuma (US).

Wearable Injectors Market Report Scope

Report Metric 

Details 

Market Revenue in 2021

$7.2 billion

Estimated Value by 2026

$11.5 billion

Growth Rate

poised to grow at a CAGR of 9.9%

Largest Share Segments

On-body Injectors, Diabetes Segment & Hospitals and Clinics

Market Report Segmentation

Type, Technology, Therapy, End User & Region

Growth Drivers

  • Shift of healthcare delivery toward homecare due to COVID-19
  • Advantages of wearable injectors in the administration of various drugs
  • Growing prevalence of chronic diseases
  • Favorable reimbursement scenario in major markets
  • Technological advancements and design development

Growth Opportunities

  • Increasing demand for biologics and mAbs
  • Unfavorable reimbursement structure in developing countries

Geographies covered

North America, Europe, APAC, MEA, and Latin America

The research report categorizes the global wearable injectors market into the following segments:

By Type

  • On-body Injector
  • Off-body Injector

By Technology

  • Spring Based
  • Motor Based
  • Rotary pump
  • Expanding battery
  • Other technology

By Therapy

  • Immuno-oncology
  • Diabetes
  • Cardiovascular disease
  • Other disease

By End User

  • Hospitals and clinics
  • Home healthcare setting

By Region

  • North America North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Recent Developments:

  • In April 2021, Medtronic launched the Infusion Set that can be worn up to seven days
  • In April 2021, Amgen acquired Five Prime Therapeutics. This acquisition—for USD 38.00 per share in cash—was focused on developing immuno-oncology and targeted cancer therapies.
  • In September 2020, Insulet Corporation expanded its presence in Sweden, Finland, Norway, and Denmark.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 23)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION
                    FIGURE 2 MARKET, BY REGION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
           TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 28)
    2.1 RESEARCH DATA
           FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 4 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (WEARABLE INJECTORS MARKET)
                               FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC.
           FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION (2020)
           FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE GLOBAL MARKET (2021–2026)
           FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 12 BOTTOM-UP APPROACH
           FIGURE 13 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 14 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET RANKING ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
    2.7 COVID-19 HEALTH ASSESSMENT
    2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE GLOBAL MARKET

3 EXECUTIVE SUMMARY (Page No. - 43)
    FIGURE 15 WEARABLE INJECTORS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
    FIGURE 18 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 19 GEOGRAPHIC SNAPSHOT OF THE GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 WEARABLE INJECTORS MARKET OVERVIEW
           FIGURE 20 SHIFT OF HEALTHCARE DELIVERY TOWARD HOMECARE DUE TO COVID-19 IS DRIVING MARKET GROWTH
    4.2 NORTH AMERICAN MARKET, BY COUNTRY AND THERAPY
           FIGURE 21 DIABETES SEGMENT COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
    4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 22 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
    4.4 GLOBAL MARKET: REGIONAL MIX
           FIGURE 23 NORTH AMERICA IS THE LARGEST MARKET FOR WEARABLE INJECTORS

5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 24 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Shift of healthcare delivery toward homecare due to COVID-19
                    5.2.1.2 Advantages of wearable injectors in the administration of various drugs
                    5.2.1.3 Growing prevalence of chronic diseases
                    5.2.1.4 Favorable reimbursement scenario in major markets
                    5.2.1.5 Technological advancements and design development
           5.2.2 RESTRAINTS
                    5.2.2.1 Preference for alternative drug delivery modes
                    5.2.2.2 High cost of wearable injectors
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for biologics and mAbs
                               FIGURE 25 US: BIOLOGIC MEDICINES IN DEVELOPMENT, 2017
           5.2.4 CHALLENGES
                    5.2.4.1 Unfavorable reimbursement structure in developing countries

6 INDUSTRY INSIGHTS (Page No. - 57)
    6.1 TECHNOLOGY ANALYSIS
    6.2 PRICING ANALYSIS
           TABLE 2 AVERAGE SELLING PRICE: WEARABLE INJECTORS
    6.3 VALUE CHAIN ANALYSIS
           FIGURE 26 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS
    6.4 ECOSYSTEM MARKET MAP
           FIGURE 27 MARKET: ECOSYSTEM MARKET MAP
    6.5 SUPPLY CHAIN ANALYSIS
           FIGURE 28 MARKET: SUPPLY CHAIN ANALYSIS
    6.6 PORTER’S FIVE FORCES ANALYSIS
           FIGURE 29 PORTER’S FIVE FORCES ANALYSIS (2020)
           TABLE 3 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           6.6.1 THREAT OF NEW ENTRANTS
           6.6.2 THREAT OF SUBSTITUTES
           6.6.3 BARGAINING POWER OF SUPPLIERS
           6.6.4 BARGAINING POWER OF BUYERS
           6.6.5 INTENSITY OF COMPETITIVE RIVALRY
    6.7 REGULATORY ANALYSIS
    6.8 PATENT ANALYSIS
           6.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS
                    FIGURE 30 GLOBAL PATENT PUBLICATION TRENDS (2015–2020)
    6.9 IMPACT OF COVID-19 ON THE MARKET

7 WEARABLE INJECTORS MARKET, BY TYPE (Page No. - 67)
    7.1 INTRODUCTION
           TABLE 4 MARKET, BY TYPE, 2019–2026 (USD MILLION)
    7.2 ON-BODY INJECTORS
           7.2.1 ON-BODY INJECTORS SEGMENT DOMINATED THE MARKET IN 2020
                    TABLE 5 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 OFF-BODY INJECTORS
           7.3.1 OFF-BODY INJECTORS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 6 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 WEARABLE INJECTORS MARKET, BY TECHNOLOGY (Page No. - 71)
    8.1 INTRODUCTION
           TABLE 7 MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    8.2 SPRING-BASED TECHNOLOGY
           8.2.1 SPRING-BASED TECHNOLOGY ENABLES THE DELIVERY OF DRUGS WITH HIGHER VOLUME AND VISCOSITY
                    TABLE 8 MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 MOTOR-DRIVEN TECHNOLOGY
           8.3.1 THESE DEVICES CAN GENERATE HIGH FORCE FOR SUBCUTANEOUS INJECTIONS OF HIGH-VISCOSITY LIQUIDS
                    TABLE 9 MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 ROTARY PUMP TECHNOLOGY
           8.4.1 THESE DEVICES SHOW HIGH PRECISION AND THE POSSIBILITY TO NOT ALTER THE FLUID PROPERTIES
                    TABLE 10 MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 EXPANDING BATTERY TECHNOLOGY
           8.5.1 EXPANDING BATTERY TECHNOLOGY SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 11 MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 OTHER TECHNOLOGIES
           TABLE 12 MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019–2026 (USD MILLION)

9 WEARABLE INJECTORS MARKET, BY THERAPY (Page No. - 78)
    9.1 INTRODUCTION
           TABLE 13 MARKET, BY THERAPY, 2019–2026 (USD MILLION)
    9.2 DIABETES
           9.2.1 HIGH PREVALENCE OF DIABETES ACROSS THE GLOBE TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
                    TABLE 14 INSULIN DEVICES AVAILABLE FOR DIABETES PATIENTS
                    TABLE 15 MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 IMMUNO-ONCOLOGY
           9.3.1 IMMUNO-ONCOLOGY SEGMENT TO WITNESS NEGATIVE GROWTH DURING THE FORECAST PERIOD
                    TABLE 16 MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 CARDIOVASCULAR DISEASES
           9.4.1 CARDIOVASCULAR DISEASES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 17 MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 OTHER THERAPIES
           TABLE 18 MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION)

10 WEARABLE INJECTORS MARKET, BY END USER (Page No. - 85)
     10.1 INTRODUCTION
             TABLE 19 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 HOSPITALS AND CLINICS
             10.2.1 HOSPITALS AND CLINICS ARE THE LARGEST END USERS OF WEARABLE INJECTORS
                        TABLE 20 MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 HOME HEALTHCARE SETTINGS
             10.3.1 HOME HEALTHCARE SETTINGS SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD
                        TABLE 21 GLOBAL MARKET FOR HOME HEALTHCARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION)

11 WEARABLE INJECTORS MARKET, BY REGION (Page No. - 89)
     11.1 INTRODUCTION
             FIGURE 31 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
             TABLE 22 MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 32 NORTH AMERICA: MARKET SNAPSHOT
             TABLE 23 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 24 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 25 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 26 NORTH AMERICA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 27 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Growing IV infusion expenditure is a key factor driving the US market.
                                     TABLE 28 US: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 29 US: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 30 US: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 31 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Rising prevalence of chronic diseases in Canada to drive the demand for drugs that can be self-administered
                                     TABLE 32 CANADA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 33 CANADA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 34 CANADA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 35 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
             FIGURE 33 EUROPE: WEARABLE INJECTORS MARKET SNAPSHOT
             TABLE 36 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 37 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 38 EUROPE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 39 EUROPE: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 40 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Availability of government support for drug development and approval to drive growth in the German wearable injectors market
                                     TABLE 41 GERMANY: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 42 GERMANY: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 43 GERMANY: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 44 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Government focus on biosimilar innovation to drive the market growth
                                     TABLE 45 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 46 UK: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 47 UK: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 48 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 100% coverage for diabetes by SHI to drive market growth in France
                                     TABLE 49 FRANCE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 50 FRANCE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 51 FRANCE: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 52 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.4 REST OF EUROPE
                        TABLE 53 ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 54 ROE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 55 ROE: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 56 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
             TABLE 57 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 58 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 59 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 60 ASIA PACIFIC: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
             TABLE 61 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Large number of patients suffering from diabetes, CVD, and other chronic conditions to drive market growth in Japan
                                     TABLE 62 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 63 JAPAN: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 64 JAPAN: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 65 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Large diabetic population to drive market growth in China
                                     TABLE 66 CHINA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 67 CHINA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 68 CHINA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 69 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Large diabetic population to drive the market for wearable injectors in India
                                     TABLE 70 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 71 INDIA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 72 INDIA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                                     TABLE 73 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 74 ROAPAC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 75 ROAPAC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 76 ROAPAC: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 77 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
             11.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER CHRONIC CONDITIONS TO DRIVE THE MARKET IN LATIN AMERICA
                        TABLE 78 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 79 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 80 LATIN AMERICA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 81 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 DEMAND FOR WEARABLE INJECTORS IN THE MANAGEMENT OF DIABETES AND CVD IS EXPECTED TO INCREASE IN THE MIDDLE EAST AND AFRICA
                        TABLE 82 CONFERENCES IN THE MIDDLE EAST AND AFRICA (2016–2018)
                        TABLE 83 MIDDLE EAST AND AFRICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 84 MIDDLE EAST AND AFRICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 85 MIDDLE EAST AND AFRICA: MARKET, BY THERAPY, 2019–2026 (USD MILLION)
                        TABLE 86 MIDDLE EAST AND AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 130)
     12.1 INTRODUCTION
             FIGURE 34 KEY MARKET DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
     12.2 REVENUE ANALYSIS OF KEY MARKET PLAYERS
             FIGURE 35 REVENUE ANALYSIS OF THE KEY PLAYERS OPERATING IN THE GLOBAL MARKET
     12.3 MARKET SHARE ANALYSIS
             FIGURE 36 WEARABLE INJECTORS MARKET SHARE, BY KEY PLAYER, 2020
     12.4 COMPETITIVE SCENARIO
             12.4.1 PRODUCT LAUNCHES
                        TABLE 87 MARKET: PRODUCT LAUNCHES (JANUARY 2018 TO JULY 2021)
             12.4.2 DEALS
                        TABLE 88 MARKET: DEALS (JANUARY 2018 TO JULY 2021)
             12.4.3 OTHER DEVELOPMENTS
                        TABLE 89 MARKET: OTHER DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
     12.5 COMPETITIVE BENCHMARKING
     12.6 COMPANY EVALUATION MATRIX
             12.6.1 STARS
             12.6.2 EMERGING LEADERS
             12.6.3 PERVASIVE PLAYERS
             12.6.4 EMERGING COMPANIES
                        FIGURE 37 GLOBAL MARKET: GLOBAL COMPANY EVALUATION MATRIX
     12.7 COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS)
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 STARTING BLOCKS
             12.7.3 RESPONSIVE COMPANIES
             12.7.4 DYNAMIC COMPANIES
                        FIGURE 38 WEARABLE INJECTORS MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS

13 COMPANY PROFILES (Page No. - 144)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
     13.1 KEY PLAYERS
             13.1.1 AMGEN INC.
                        TABLE 90 AMGEN INC.: BUSINESS OVERVIEW
                        FIGURE 39 AMGEN INC.: COMPANY SNAPSHOT (2020)
             13.1.2 MEDTRONIC PLC
                        TABLE 91 MEDTRONIC PLC: BUSINESS OVERVIEW
                        FIGURE 40 MEDTRONIC PLC: COMPANY SNAPSHOT (2020)
             13.1.3 INSULET CORPORATION
                        TABLE 92 INSULET CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 INSULET CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.4 YPSOMED
                        TABLE 93 YPSOMED: BUSINESS OVERVIEW
                        FIGURE 42 YPSOMED: COMPANY SNAPSHOT (2020)
             13.1.5 UNITED THERAPEUTICS CORPORATION
                        TABLE 94 UNITED THERAPEUTICS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 43 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.6 SUBCUJECT
                        TABLE 95 SUBCUJECT: BUSINESS OVERVIEW
             13.1.7 ENABLE INJECTIONS
                        TABLE 96 ENABLE INJECTIONS: BUSINESS OVERVIEW
             13.1.8 CEQUR SA
                        TABLE 97 CEQUR SA: BUSINESS OVERVIEW
             13.1.9 SENSILE MEDICAL (A PART OF GERRESHEIMER)
                        TABLE 98 SENSILE MEDICAL: BUSINESS OVERVIEW
     13.2 OTHER PLAYERS
             13.2.1 ATS AUTOMATION
                        TABLE 99 ATS AUTOMATION: BUSINESS OVERVIEW
                        FIGURE 44 ATS AUTOMATION: COMPANY SNAPSHOT (2020)
             13.2.2 WEST PHARMACEUTICAL SERVICES, INC.
                        TABLE 100 WEST PHARMACEUTICAL SERVICES, INC.: BUSINESS OVERVIEW
                        FIGURE 45 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2020)
             13.2.3 TANDEM DIABETES CARE
                        TABLE 101 TANDEM DIABETES CARE: BUSINESS OVERVIEW
                        FIGURE 46 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2020)
             13.2.4 ZEALAND PHARMA A/S
                        TABLE 102 ZEALAND PHARMA A/S: BUSINESS OVERVIEW
                        FIGURE 47 ZEALAND PHARMA A/S: COMPANY SNAPSHOT (2020)
             13.2.5 SONCEBOZ
                        TABLE 103 SONCEBOZ: BUSINESS OVERVIEW
             13.2.6 NOBLE INTERNATIONAL LLC (AN APTAR PHARMA COMPANY)
                        TABLE 104 NOBLE INTERNATIONAL LLC: BUSINESS OVERVIEW
                        FIGURE 48 NOBLE INTERNATIONAL LLC: COMPANY SNAPSHOT (2020)
             13.2.7 ELCAM DRUG DELIVERY DEVICES (E3D)
                        TABLE 105 ELCAM DRUG DELIVERY DEVICES: BUSINESS OVERVIEW
             13.2.8 BESPAK EUROPE LTD.
                        TABLE 106 BESPAK EUROPE LTD.: BUSINESS OVERVIEW
                        FIGURE 49 BESPAK EUROPE LTD.: COMPANY SNAPSHOT (2020)
             13.2.9 STEVANATO GROUP
                        TABLE 107 STEVANATO GROUP: BUSINESS OVERVIEW
             13.2.10 SORREL MEDICAL
                        TABLE 108 SORREL MEDICAL: BUSINESS OVERVIEW
             13.2.11 WEIBEL CDS
                        TABLE 109 WEIBEL CDS: BUSINESS OVERVIEW
             13.2.12 NEUMA LLC
                        TABLE 110 NEUMA: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 183)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the wearable injectors market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The wearable injectors market comprises several stakeholders such as wearable injector manufacturers and distributors and regulatory organizations. The demand side of this market is characterized by hospitals & clinics, and home healthcare setting.

Various primary sources from both, the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents for wearable injectors market is provided below:

Wearable Injectors Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by type, by technology, by therapy, by end user, and by region).

Data Triangulation

After arriving at the market size, the total wearable injectors market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, analyze, and forecast the size of the wearable injectors market on the basis of type, technology, therapy, end user and region.
  • To provide detailed information on the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To forecast the size of the market segments with respect to North America, Europe, Asia Pacific, latin America and Middle East and Africa.
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as product launches, partnerships, acquisitions and other developments in the market.
  • To benchmark players within the wearable injectors market using the Competitive Leadership Mapping framework which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific wearable injectors market into South Korea, New Zealand, and other countries.
Report Code
MD 6659
Published ON
Jul, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Wearable Injectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback